Home / Pharmaceutical company intelligence
RASCO PHARMA logo
Pharmaceutical company intelligence

RASCO PHARMA

Pharmaceutical manufacturer · Lahore · Pakistan

Lahore pharmaceutical manufacturer operating since 2004 with generic medicines, quality-control infrastructure and multiple dosage forms.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date17 Aug 2026Newest effective date among published current price records
Corporate profile evidence5 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Pharmaceutical manufacturer
Address
5.5 KM, Near Ali Raza Abad, Holiday Park, Plot No. 27, Raiwind Road, Lahore, Pakistan
Phone
+92 42 35230774-5
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000530 Rasco Pharma (Pvt) Ltd. · Punjab
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000530 84 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Url source ↗ Contact Page Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx83public portfolio records represented
REG67unique registrations represented
IDX83indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR77current validated price records
G34generic molecules in indexed catalogue
DF7dosage-form groups
TA8therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage93%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage87%
priced packs safely normalized per unit
Comparable-market coverage87%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixRASCO PHARMAShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/rasco-pharmaGenerated 23 Sep 2026Anti-infectives45 · 54%CNS & mental health15 · 18%Pain & musculoskeletal11 · 13%Gastrointestinal & hepatology5 · 6%Cardiovascular2 · 2%Respiratory & allergy2 · 2%Hematology & thrombosis2 · 2%Other therapeutic areas1 · 1%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioRASCO PHARMADistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/rasco-pharmaGenerated 23 Sep 202683presentationsTablet47 · 57%Injection11 · 13%Capsule10 · 12%Suspension10 · 12%Infusion3 · 4%Solution1 · 1%Other forms1 · 1%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionRASCO PHARMACurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/rasco-pharmaGenerated 23 Sep 202672comparable productsBelow peer median13 · 18%Near peer median33 · 46%Above peer median26 · 36%Company median price position+3.8%Lowest-price equivalents1Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsRASCO PHARMACompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/rasco-pharmaGenerated 23 Sep 2026Mediate Pharmaceutical Pvt Ltd29 shared85% overlapNeutro Pharma (Pvt.) Ltd.,26 shared76% overlapZafa Pharmaceutical Laboratories (P…25 shared74% overlapAmarant Pharmaceuticals Private Lim…25 shared74% overlapPulse Pharmaceuticals (Pvt.) Ltd.25 shared74% overlapNovaMed Pharmaceuticals(Pvt.)Ltd24 shared71% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives45 products · 54%
CNS & mental health15 products · 18%
Pain & musculoskeletal11 products · 13%
Gastrointestinal & hepatology5 products · 6%
Cardiovascular2 products · 2%
Respiratory & allergy2 products · 2%
Hematology & thrombosis2 products · 2%
Fluids & supportive care1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Analgesics / NSAIDs10 products · 12%
Third-generation cephalosporins8 products · 10%
Macrolide antibacterials7 products · 8%
Fluoroquinolone antibacterials6 products · 7%
Other systemic antibacterials6 products · 7%
Antipsychotics5 products · 6%
Antiepileptics5 products · 6%
Proton pump inhibitors5 products · 6%
Formulation footprint

Dosage forms

Tablet47 products
Injection11 products
Capsule10 products
Suspension10 products
Infusion3 products
Solution1 products
Syrup1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 Rasco PharmadolParacetamol 6presentations 120 mg/5 mL, 250 MG/5 mL, 500 mg · Suspension, Tablet #2 ResgylMetronidazole 5presentations 200 mg, 400 mg, 500 mg/100 mL · Tablet, Infusion #3 B-LexCephalexin 4presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Capsule #4 Le-TactLevetiracetam 4presentations 250 mg, 500 mg, 500 mg/5 mL · Tablet, Injection, Solution #5 PrismaOmeprazole 4presentations 20 mg, 40 mg · Tablet, Capsule, Injection #6 ResfenIbuprofen 4presentations 200 mg, 400 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median1318% of comparable products
Near market median33within ±5% of median
Above market median2636% of comparable products
Lowest-price equivalents1ties included
Company median price position +3.8% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Benazole 1 mgRisperidone · Tablet · 2x10's PKR 11.97/tablet-48.6% vs market median Benazole 2Tablet 2 mgRisperidone · Tablet · 2x10's PKR 19.45/tablet-47.5% vs market median Lortec 10 mgLoratadine · Tablet · 10'S PKR 8.38/tablet-41.7% vs market median Rasco Pharmadol 250 MG/5 mLParacetamol · Suspension · 90ml PKR 1.19/mL-22.5% vs market median Benazole 3 3 mgRisperidone · Tablet · 1x10's PKR 45.88/tablet-21.2% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 29shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 26shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 25shared generics Amarant Pharmaceuticals Private Limited143 products · 61 generics 25shared generics Pulse Pharmaceuticals (Pvt.) Ltd.116 products · 48 generics 25shared generics NovaMed Pharmaceuticals(Pvt.)Ltd187 products · 62 generics 24shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers67Distinct registrations among indexed, published, presentation-validated products only
Verified price observations159
Products with a verified price83
Products with multiple price observations76
Source records with multiple versions82
Latest portfolio source check22 Sep 2026
Latest effective price date17 Aug 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

67 unique registration(s) · 83 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
A.Z Ko Azithromycin 250 mg Tablet 10's 040180 PKR 525.25 PKR 52.53/tablet 12% above median
A.Z Ko Azithromycin 500 mg Tablet 6's 107068 PKR 412.69 PKR 68.78/tablet 19% below median
Aquaras Water for Injection 5 mL Injection 5mlx100's 085498 PKR 1,101.08 PKR 2.20/mL 11% above median
AZ-Ko Azithromycin 200 mg/5 mL Suspension 15ml 041630 PKR 329.13 PKR 21.94/mL Near median
AZ-Ko Azithromycin 250 mg Capsule 1x6's 050202 PKR 247.84 PKR 41.31/capsule 17% below median
AZ-Ko Azithromycin 250 mg Capsule 10's 050202 PKR 508.66 PKR 50.87/capsule Near median
B-Lex Cephalexin 125 mg/5 mL Suspension 60ml 038951 PKR 131.37 PKR 2.19/mL 18% above median
B-Lex Cephalexin 250 mg/5 mL Suspension 60ml 038952 PKR 227.11 PKR 3.79/mL 18% above median
B-Lex Cephalexin 500 mg Capsule 12's 038961 PKR 325.45 PKR 27.12/capsule 12% below median
B-Lex Cephalexin 250 mg Capsule 12's 050655 PKR 164.79 PKR 13.73/capsule 12% below median
Bactiphin Ceftriaxone 250 mg Injection 1Vial 050657 PKR 201.47 PKR 201.47/vial/unit Near median
Bactiphin Ceftriaxone 500 mg Injection 1Vial 050658 PKR 350.17 PKR 350.17/vial/unit 8% above median
Bactiphin Ceftriaxone 1 g Injection 1Vial 050659 PKR 640.29 PKR 640.29/vial/unit 7% above median
Benazole Risperidone 1 mg Tablet 2x10's 057203 PKR 239.36 PKR 11.97/tablet 49% below median
Benazole 2Tablet Risperidone 2 mg Tablet 2x10's 057204 PKR 388.96 PKR 19.45/tablet 47% below median
Benazole 3 Risperidone 3 mg Tablet 1x10's 059693 PKR 458.79 PKR 45.88/tablet 21% below median
Cip-Rx Ciprofloxacin 250 mg Tablet 1x10's 040156 PKR 259.32 PKR 25.93/tablet Near median
Cip-Rx Ciprofloxacin 500 mg Tablet 1x10's 040157 PKR 535.55 PKR 53.56/tablet 25% above median
Cip-Rx Ciprofloxacin 200 mg IV infusion 100ml x1's 078929 PKR 199.47 PKR 1.99/mL 12% below median
Diazepam Diazepam 5 mg Tablet 3X10's 065714 PKR 40.22 PKR 1.34/tablet Near median
Diazepam Diazepam 2 mg Tablet 3X10's 065721 PKR 24.96 PKR 0.83/tablet Near median
Diazepam-5 Diazepam 5 mg Tablet 1000's Jar 065714 PKR 1,300.30 — No comparator
Fexatin Fluoxetine 20 mg Tablet 1x10's 040184 PKR 129.66 PKR 12.97/tablet Near median
Goronil Losartan 50 mg Tablet 2x10's 046777 PKR 398.94 PKR 19.95/tablet Near median
Ixalt Artemether + Lumefantrine 20 mg + 120 mg Tablet 16's 063157 PKR 638.30 PKR 39.89/tablet Near median
Ixalt Artemether 80 mg Injection 6's 080018 PKR 1,196.82 PKR 199.47/vial/unit Near median
Kabrokin Carbamazepine 200 mg Tablet 30's 116636 PKR 324.50 PKR 10.82/tablet Near median
Keukin Quetiapine 200 mg Tablet 10's 087503 PKR 1,057.11 PKR 105.71/tablet 22% above median
Le-Tact Levetiracetam 500 mg Tablet 3X10's 067957 PKR 3,474.35 PKR 115.81/tablet 22% above median
Le-Tact Levetiracetam 250 mg Tablet 3X10's 067958 PKR 2,095.41 PKR 69.85/tablet 26% above median
Le-Tact Levetiracetam 500 mg/5 mL Oral solution 60ml 074417 PKR 845.69 PKR 14.09/mL Near median
Le-Tact Levetiracetam 500 mg/5 mL Injection 5mlx1.s 098251 PKR 595.35 — No comparator
Levofloxa-250 Levofloxacin 250 mg Tablet 1x10's 040170 PKR 498.68 PKR 49.87/tablet Near median
Levofloxa-500 Levofloxacin 500 mg Tablet 10's 041626 PKR 829.80 PKR 82.98/tablet Near median
Lortec Loratadine 10 mg Tablet 10'S 032424 PKR 83.78 PKR 8.38/tablet 42% below median
Lortec Loratadine 5 mg/5 mL Syrup 60ml 032425 PKR 95.74 PKR 1.60/mL 5% below median
Moxiline Moxifloxacin 400 mg Tablet 1X5's 059698 PKR 978.41 PKR 195.68/tablet 6% above median
Nilclot Clopidogrel 75 mg Tablet 1X10's 038970 PKR 279.26 PKR 27.93/tablet Near median
Pharmatran Sulfamethoxazole + Trimethoprim 200 mg + 40 mg / 5 mL Suspension 50ml 032406 PKR 46.76 PKR 0.94/mL 37% above median
Pharmatran DS Sulfamethoxazole + Trimethoprim 800 mg + 160 mg Tablet 100's Jar 032417 PKR 493.95 — No comparator
Pharmatran DS Sulfamethoxazole + Trimethoprim 800 mg + 160 mg Tablet 10 x 10's 032417 PKR 969.34 PKR 9.69/tablet Near median
Pharmatran Paediatric Sulfamethoxazole + Trimethoprim 40 mg/5 mL + 200 mg/5 mL Suspension 400ml 032406 PKR 153.75 PKR 0.38/mL 11% below median
Prisma Omeprazole 20 mg Capsule 10x10's 043352 PKR 2,037.17 PKR 20.37/capsule Near median
Prisma Omeprazole 20 mg Enteric-coated tablet 10's 043352 PKR 212.17 PKR 21.22/tablet 12% above median
Prisma Omeprazole 40 mg Capsule 2x7's 069394 PKR 514.96 PKR 36.78/capsule 6% above median
Prisma Omeprazole 40 mg IV injection 1 vial 082762 PKR 598.41 PKR 598.41/vial/unit Near median
Prisma-20 Omeprazole 20 mg Capsule 2x7's 043352 PKR 296.61 PKR 21.19/capsule 8% above median
Quantum Quetiapine 100 mg Tablet 1X10's 067964 PKR 845.69 PKR 84.57/tablet 14% above median
Ras-Q Hydroxychloroquine 200 mg Tablet 50.s 101926 PKR 830.97 — No comparator
Ras-Q Hydroxychloroquine 200 mg Tablet 30.s 101926 PKR 498.59 — No comparator
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). RASCO PHARMA — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/rasco-pharma/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.